What is Entyvio and What is it Used For?
Entyvio contains the active substance vedolizumab. Vedolizumab belongs to a group of biological medicines called monoclonal antibodies.1
Entyvio is used to treat the signs and symptoms in adults of:1
- moderately to severely active ulcerative colitis
- moderately to severely active Crohn’s disease
How Does Your Medication Work?
Vedolizumab blocks a protein on the surface of white blood cells that get into the gut and cause inflammation in ulcerative colitis and Crohn’s disease. By doing this, the amount of inflammation is reduced.1
Entyvio Patient Welcome Pack
This welcome pack has been created for patients who have been prescribed Entyvio. It contains detailed information about your new medicine. You may have already been given a printed copy of this informative pack by your healthcare professional but you can also view or download an electronic copy here.
If you have been prescribed Entyvio and get any side effects, talk to your doctor, pharmacist or nurse.
This includes any possible side effects not listed within this website or in the Patient Information Leaflet.
Adverse events should be reported. In the United Kingdom, reporting forms and information can be found at www.mhra.gov.uk/yellowcard.
Adverse events should also be reported to Takeda on 01628 537900 or e-mail DSO-UK@takeda.com